All In Biotech

Drug Trial Radar · NCT05513742

A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer

A Phase 2 Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer Who Have Received Two or Three Prior Systemic Chemotherapy Regimens

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

49

Actual

Start

Dec 8, 2022

Primary completion

May 15, 2025

Study completion May 15, 2025

Sponsor

Lead sponsor
Compass TherapeuticsIndustry
Sponsor type
Industry
First posted
Aug 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed as an open-label, adaptive Simon Two-Stage study to evaluate the efficacy of CTX-009 in patients with metastatic colorectal cancer. A Simon Two-Stage adaptive design will enroll approximately 37 patients into Stage 1, and if criteria are met to move to Stage 2, an additional 47 patients will be enrolled.

Conditions

  • Metastatic Colorectal Cancer
  • Colon Cancer
  • Rectal Cancer

Interventions

  • CTX-009Drug

    IV infusion administered on day 1 and 15 of every 28-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response RateTime frame: From first dose of CTX-009 until treatment discontinuation (an average of 16 weeks)

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Genesis Cancer and Blood Institute

    Hot Springs, Arkansas

  • Florida Cancer Specialists & Research Institute - South

    Fort Myers, Florida

  • Florida Cancer Specialists & Research Institute - North

    St. Petersburg, Florida

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • Zangmeister Cancer Center

    Columbus, Ohio

  • SCRI Oncology Partners

    Nashville, Tennessee

  • Mary Crowley Cancer Research

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.